The Nijmegen ultra-sensitive Bethesda Assay detects very low-titer factor VIII inhibitors in patients with congenital and acquired hemophilia A

An inhibitor can develop in congenital hemophilia A (HA) patients against exogenous infused factor (F)VIII, whereas in acquired HA (AHA) inhibitors initially develop against endogenous FVIII. Inhibitors can be detected with the Nijmegen Bethesda Assay (NBA), which has an international cut-off level of 0.60 Nijmegen Bethesda Units/mL (NBU/mL). Thereby, very low-titer inhibitors may remain undetected.

Source: Thrombosis Research - October 10, 2023 Category: Hematology Authors: Lars L.F.G. Valke, Marieke J.A. Verhagen, Bart T.P.M. Mulders, Robert Polenewen, Nicole M.A. Blijlevens, Joop H. Jansen, Hassan Mansouritorghabeh, Einas Elsheikh, Birgit M. Reipert, Peter L. Turecek, James S. O'Donnell, Sanna R. Rijpma, Saskia E.M. Schols Tags: Full Length Article Source Type: research